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Abstract
In the era of evidence-based medicine, large, randomized, controlled, multicenter studies represent the “summit of
evidence”. In contrast to specialties like cardiology, the majority of randomized, controlled trials in critical care
medicine, however, have failed to demonstrate a survival benefit; notably, despite encouraging results from
experimental and phase-II clinical studies. The difficulty in translating our theoretical knowledge into successful
multicenter randomized, controlled trials and subsequent treatment recommendations may represent one reason,
why the mortality of septic shock still averages between 40-60%, although our knowledge about the underlying
pathophysiology has considerably increased and international guidelines have widely been implemented. The
present article elucidates some of the difficulties in translating research from bench to bedside.
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Introduction
In the era of evidence-based medicine, large, rando-
mized, controlled, multicenter studies (together with
meta-analyses) represent the “summit of evidence” [1].
In contrast to specialties like cardiology, the majority of
randomized, controlled trials (RCT) in critical care med-
icine, however, have failed to demonstrate a survival
benefit [2]; notably, despite encouraging results from
experimental and phase-II clinical studies. The difficulty
in translating our theoretical knowledge into successful
multicenter RCTs and subsequent treatment recommen-
dations may represent one reason, why the mortality of
septic shock still averages between 40-60% [3], although
the understanding of the underlying pathophysiology
has considerably increased and international guidelines
have widely been implemented.
Just two examples for this dilemma: In 1995, Hebert-
son et al. described an attenuation of the decrease in
left-ventricular contractility by tumor necrosis factor-
alpha-(TNFa) antibodies in endotoxemic pigs [4]. In the
same year, Givner and colleagues reported a reduction
in mortality of newborn rats with group B streptococcal
disease due to the use of TNFa-antibodies [5]. The sub-
sequent pilot study on nine patients with septic shock
revealed no side effects concerning the use of TNFa-
antibodies as an adjunct therapy regardless of the admi-
nistered dose [6]. Only a few months later, the RCT
with 141 patients receiving either placebo or TNF-
receptor:Fc fusion protein in three different dosing regi-
mens not only failed to show any survival benefit, but
even suggested an increase in mortality associated with
higher doses [7].
The “VAsopressin and Septic Shock Trial” (VASST)
represents another, more recent example. Whereas there
was consistent and extensive evidence from numerous
experimental [8,9] as well as small clinical trials [10-12]
about the efficacy and benefit of a supplementary low-
dose infusion of arginine vasopressin (AVP) on catecho-
lamine requirements and several other outcome mea-
sures in septic shock, the large, multicenter VASST
study revealed no significant difference in mortality
between sole norepinephrine and combined AVP and
norepinephrine in the overall population [13].
But even if the initial RCT has been successful, like for
the use of stress-dose corticosteroids in septic shock
[14], confirmation studies may turn out negative [15].
This may lead to a so-called “pendulum effect” [16],
thereby leaving clinicians in frustration and uncertainty
about how to treat their patients. The present article
elucidates some of the difficulties in translating our
knowledge from bench to bedside.
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clinical research
F i r s to fa l l ,w es h o u l dk e e pi nm i n dt h ee l e m e n t a r yd i f -
ferences between experimental and clinical trials: precli-
nical studies are usually performed in young and healthy
animals, whereas the majority of patients in the inten-
sive care unit (ICU) suffer from multiple and severe co-
morbidities such as chronic heart failure, diabetes,
chronic kidney failure. Furthermore, preclinical research
allows a well-defined injury (e.g. endotoxemia, cecal liga-
tion and puncture, pneumonia) and perfectly standar-
dized therapeutic interventions. Contrary, study
populations of large RCTs are characterized by different
sources of sepsis (e.g. pneumonia, abdominal infections,
surgical site infections) and concomitant therapies are
mostly left to the discretion of the attending physician.
To increase the clinical relevance of experimental
research, it has been suggested to use “higher fidelity
animal models” in the future [17]. Among others, these
are characterized by inclusion of older animals and dif-
ferent genetic lines. The fidelity is further increased by
the use of “two-hit models” (e.g. pneumonia after fol-
lowing a trauma or burn injury) that mimic nosocomial
sepsis secondary to an initial insult more realistically
than “one-hit models”.
An elementary difference between research in cardiol-
ogy and critical care is that the pathophysiology and
clinical symptoms between different patients with myo-
cardial infarction, for example, are almost identical and
quite specific, whereas critical care syndromes like the
“systemic inflammatory response syndrome” (SIRS) or
“acute respiratory distress syndrome” (ARDS) can be
caused by numerous pathophysiological pathways and
their diagnosis is based on rather unspecific definitions.
As a consequence, the development of definite treat-
ment strategies is more difficult. This hypothesis is sup-
ported by the fact that the current guidelines of the
Surviving Sepsis Campaign contain 53 class I recom-
mendations with only 8 being classified as grade A,
whereas the guidelines for the treatment of ST-segment
elevation myocardial infarction, for example, include 93
class I recommendations. Against this background, the
first step in improving translational research in critical
care is to increase the knowledge of the underlying
pathophysiology by experimental research.
Patient characteristics in RCTs
A major problem of clinical RCTs is represented by their
heterogeneity in several aspects: the severity of illness,
the source of infection, the timing of intervention, and
concomitant therapies. Severe sepsis and septic shock are
associated with a different baseline risk of death. Inclu-
sion of both, severe sepsis and septic shock, without clear
differentiation will mix up the effects on both patient
cohorts. In addition, from a statistical point of view
demonstrating a survival benefit becomes more difficult,
if the mortality in the control group is reduced by includ-
ing patients with septic shock and severe sepsis as com-
pared to a control group including only septic shock
patients. Furthermore, RCTs often not only include
patients with sepsis deriving from different foci (e.g.
pneumonia, intraabdominal sepsis, surgical site infection)
but also patients with systemic inflammation due to a
non-septic cause (e.g. pancreatitis, post-cardiopulmonary
resuscitation, burns). These different pathophysiological
pathways further increase the heterogeneity of the study
population and, thereby, the risk of failure.
Since it may be assumed from the past that specific
interventions are likely to fail if tested in a heteroge-
neous population (so-called “one-size-fits-all concept”),
it appears appropriate to target study interventions for
selected patient cohorts (e.g. patients with postoperative,
ventilator-associated pneumonia). In these highly
selected cohorts, it is more likely to unmask a specific
intervention as “clearly beneficial”, “clearly harmful”,o r
“probably futile”. Such a concept seems to be successful
in other specialties with generally stricter inclusion cri-
teria [18]. On the downside, trials with very strict inclu-
sion criteria are likely to be terminated due to slow
recruitment. It is one major goal for the next years to
find the right balance in defining severity of illness and
patient characteristics for successful RCTs [19].
Timing of the study intervention
Closely associated with the severity of illness is the tim-
ing of intervention, i.e. the time window from the point
of diagnosis up to study inclusion and initiation of the
therapy. On the one hand, a wide time window for
inclusion, may increase the chance to recruit more
patients in a shorter time period. On the other hand,
more patients will present with progressive disease and
even multiple organ failure at the start of treatment,
which may negatively influence the potential benefit of
any intervention [19].
A recent negative trial of fluid therapy in severe sepsis
recruited patients who already fulfilled the predefined
criteria of normovolemia prior the inclusion [20],
thereby representing an example of suboptimal patient
selection. If e.g. two fluids are compared for volume
therapy, it is essential to include patients in the very
early phase of disease, in which they are actually hypo-
volemic. In normovolemic patients, however, any exces-
sive fluid therapy regardless of the individual type may
only proof deleterious [21].
Several clinical trials of anti-inflammatory mediators
used liberal inclusion windows [22-24] notwithstanding
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patients depends on the time elapsed since the initial
injury [25]. The typical time course starts with an early
phase of hyperinflammation, where anti-inflammatory
mediators may theoretically be promising [26], and a
prolonged period of immunosuppression, where anti-
inflammatory treatment may supposedly be detrimental.
Acquisition of patients in the very early phase of criti-
cal illness requires optimal research infrastructure with
minimal administrative burden. Since the most severely
ill patients need immediate treatment at the time of
admission, a delay of several hours until the start of
study intervention may miss its “golden hour” and may
be inadequately judged as futile or harmful.
Heterogeneity in concomitant treatments and
end point selection
The heterogeneity in concomitant treatments represents
another very important confounder. Whereas most sep-
sis trials provide more or less strict guidelines for the
examined intervention, the concomitant treatment is
mostly left to the discretion of the attending physician.
It is obvious, that controversially discussed and differ-
ently handled measures like the type of fluid or vaso-
pressor agent used, the antibiotic regimen, hand hygiene
compliance, prevalence of multidrug-resistant micro-
bials, ventilatory settings, sedation strategies, glucose
control, ulcer or thromboembolic prophylaxis may influ-
ence the patients’ outcome in a significant way. These
therapeutic strategies often differ not only between
countries, but also between hospitals and even doctors
[1,19]. Notably, these confounding differences in co-
treatments may have a considerable higher impact on
the trial endpoint than the study intervention itself.
Therefore, relevant concomitant treatment strategies
should be defined as strictly as the investigated therapy.
The guidelines of the Surviving Sepsis Campaign repre-
sent an international standard for some but not all co-
treatments [27]. At least, there should be a minimum
standard guaranteed in all institutions, i.e. by applying
simple checklists like the “fast hug” system [28].
Another way of controlling heterogeneous co-interven-
tions is to investigate not a single but a bundle of thera-
peutic interventions, e.g. the “sepsis bundles” [29], or
defined protocols, such as the “early goal directed ther-
apy” approach by Rivers et al. [30].
Finally, the problem of selecting appropriate end
points for RCTs should be addressed. Mortality still
represents the most impressive and the most objective
one. However, even this “unassailable” end point is asso-
ciated with some limitations. As discussed earlier,
potential beneficial effects of a treatment can be neutra-
lized, if patient populations are not defined adequately.
In addition, death in the ICU is often preceded by end-
o f - l i f ed e c i s i o n s .T h i sp r o c e s sm a yn o ti n f l u e n c et h e
absolute rate of mortality but potentially the time of
death and thereby survival time. Furthermore, a reduc-
tion in mortality does not provide any information
about the mechanism of action of the interventions stu-
died. Therefore, alternative or secondary outcome vari-
ables are warranted. Organ function scores, ventilator-
free days, ICU stay, health-adjusted quality of life or
quality-adjusted life years represent some examples.
However, the value of differences in these secondary
outcomes without changes in mortality remains to be
determined.
Future perspectives
Last but not least the increasing relevance of theragnos-
tics should be mentioned. Theragnostic is best described
as the use of biomarkers to identify patients, who are
most likely to benefit from a certain intervention. In
septic patients, procalcitonin represents an example for
a biomarker that can be used to guide antibiotic treat-
ment [31]. This approach of individualized medicine can
be extended to pharmacogenomic biomarkers that give
information about the probability of success for the
individual compound, similar to the treatment of cancer.
In this context, genetic differences between individuals
will increasingly influence and potentially guide therapies
in critical care. Concerning the use of AVP in septic shock
patients, Dr. Nakada and colleagues reported that a speci-
fic genetic variation in leucyl/cystinyl aminopeptidase
(=vasopressinase, the enzyme that metabolizes AVP) is
associated with 28-day mortality in septic shock and with
biologic effects on AVP clearance [32]. By determining
this genetic variation, the probability of success of AVP
therapy could be specified. In addition, dose selection of
AVP might be guided by this knowledge. For example, if a
patient has a genetically determined, increased AVP clear-
ance, higher doses might be chosen for the treatment than
for a patient with a low AVP clearance.
Conclusions
In summary, improvement of translational research in
sepsis and critical illness should consist of a bi-lateral
approach. On the one hand, the clinical relevance of
preclinical studies can be increased by the use of “high-
fidelity” and “two-hit” animal models. On the other
hand, RCTs should be designed to optimize time of
study intervention, limit heterogeneity in patient charac-
terization, standardize concomitant treatments and
investigate not a single but bundles of interventions. As
a consequence, RCTs will probably become smaller in
sample size, but hopefully will provide more valuable
evidence for the benefit of our patients.
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